138 related articles for article (PubMed ID: 15716329)
21. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
23. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
25. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
26. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
de Vinuesa SG; Goicoechea M; Kanter J; Puerta M; Cachofeiro V; Lahera V; Gómez-Campderá F; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S206-12. PubMed ID: 17130263
[TBL] [Abstract][Full Text] [Related]
27. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
[TBL] [Abstract][Full Text] [Related]
28. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
29. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
Suzuki R; Honda H; Niikura K; Akizawa T
Clin Exp Hypertens; 2012; 34(2):125-31. PubMed ID: 21967019
[TBL] [Abstract][Full Text] [Related]
30. Renal sensitivity to angiotensin II in type 1 diabetes.
Björck S; Aurell M; Bresäter LE; Herlitz H; Welin L; Wikstrand J
Scand J Urol Nephrol; 1990; 24(4):267-73. PubMed ID: 2274750
[TBL] [Abstract][Full Text] [Related]
31. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Gounder VK; Arumugam S; Arozal W; Thandavarayan RA; Pitchaimani V; Harima M; Suzuki K; Nomoto M; Watanabe K
Int Immunopharmacol; 2014 Feb; 18(2):282-9. PubMed ID: 24291173
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
[TBL] [Abstract][Full Text] [Related]
33. Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.
Ritt M; Ott C; Raff U; Schneider MP; Schuster I; Hilgers KF; Schlaich MP; Schmieder RE
Am J Kidney Dis; 2009 Feb; 53(2):281-9. PubMed ID: 19100670
[TBL] [Abstract][Full Text] [Related]
34. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker.
Skov K; Eiskjaer H; Hansen HE; Madsen JK; Kvist S; Mulvany MJ
Hypertension; 2007 Jul; 50(1):89-95. PubMed ID: 17485597
[TBL] [Abstract][Full Text] [Related]
35. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
[TBL] [Abstract][Full Text] [Related]
36. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
Skov J; Pedersen M; Holst JJ; Madsen B; Goetze JP; Rittig S; Jonassen T; Frøkiaer J; Dejgaard A; Christiansen JS
Diabetes Obes Metab; 2016 Jun; 18(6):581-9. PubMed ID: 26910107
[TBL] [Abstract][Full Text] [Related]
37. Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome.
Brillante DG; O'Sullivan AJ; Brillante RE; Howes LG
Blood Press; 2009; 18(3):142-8. PubMed ID: 19462315
[TBL] [Abstract][Full Text] [Related]
38. Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: a dose response study.
Pedersen EB; Thomsen IM; Fjordside LS
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1578-85. PubMed ID: 16364829
[TBL] [Abstract][Full Text] [Related]
39. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
Tofé Povedano S; García De La Villa B
J Clin Hypertens (Greenwich); 2009 Aug; 11(8):426-31. PubMed ID: 19695030
[TBL] [Abstract][Full Text] [Related]
40. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.
Yamagishi S; Takeuchi M; Inoue H
Drugs Exp Clin Res; 2005; 31(2):45-51. PubMed ID: 15929605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
